DexCom Q4 revenue beat at $1.114B, up 8% Y/Y, but EPS missed at $0.45 vs. $0.50 consensus. FY25 guidance reaffirmed with $4.6B revenue target and 21% operating margin. Get stock picks, daily rankings, ...

When it comes to the diabetes space, Dexcom is one of the heavy hitters. Its work in the continuous glucose monitoring space has put it on the map. In 2018, its Dexcom G6, an integrated continuous ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

Researchers who use Fitabase to capture data from Fitbit and Garmin devices will soon be able to capture a new kind of data: continuous glucose monitoring data from Dexcom products. The ability to ...

Elsewhere, the company's Casgevy, approved some two years ago to treat two rare blood disorders, could also make commercial ...

DexCom's Q3 performance shows impressive organic growth rates and increased revenue guidance for 2023. The company's strategic focus on international markets and expanding customer bases indicates ...

Eli Lilly and Company LLY announced that it has inked a development deal with DexCom, Inc. DXCM to integrate the latter’s continuous glucose monitoring (CGM) products and tools into Lilly’s Connected ...

As the United States approaches 2026, key structural shifts in retirement and healthcare financing are poised to affect how ...

After what the diabetes data company has described as its best year ever, Dexcom is starting to spend its extra cash—first on its inaugural Super Bowl ad, and now to launch its very own venture ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. A warning letter posted Tuesday by the Food and Drug ...